1. Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease
- Author
-
Ichikawa, Hiroya, Yakushijin, Kimikazu, Kurata, Keiji, Tsuji, Takahiro, Takemoto, Naoko, Joyce, Miki, Okazoe, Yuri, Takahashi, Ruri, Matsumoto, Sakuya, Sakai, Rina, Kitao, Akihito, Miyata, Yoshiharu, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Murayama, Tohru, Matsuoka, Hiroshi, and Minami, Hironobu
- Abstract
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis of SOS/VOD is associated with improved clinical outcomes. In 2023, the refined European Society for Blood and Marrow Transplantation diagnostic and severity criteria (refined EBMT criteria 2023) have been advocated. The revision has introduced new diagnostic categories, namely; probable, clinical, and proven SOS/VOD. In addition, the Sequential Organ Failure Assessment (SOFA) score has been newly incorporated into the SOS/VOD severity grading. We performed a retrospective analysis to evaluate the utility of these criteria. We analyzed 161 cases who underwent allogeneic HSCT. We identified 53 probable, 23 clinical, and 4 proven SOS/VOD cases. Probable SOS/VOD was diagnosed a median of 5.0 days earlier (interquartile range: 2–13 days, P< 0.001) than that of clinical SOS/VOD. The development of probable SOS/VOD alone was associated with a significantly inferior survival proportion compared to non-SOS/VOD (100-day survival, 86.2% vs. 94.3%, P= 0.012). The SOFA score contributed to the prediction of prognosis. Consequently, the refined EBMT criteria 2023 demonstrated the utility of SOS/VOD diagnosis and severity grading. Further investigations and improvements in these criteria are warranted.
- Published
- 2024
- Full Text
- View/download PDF